Moderate

Evaluation of haematuria (visible and non-visible)

haematuria · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Structured work-up distinguishing glomerular (nephrological) from urological bleeding and identifying malignancy, stones or infection. Visible haematuria and non-visible haematuria with risk factors warrant prompt urological assessment; glomerular patterns go to nephrology.

Red flags

  • Visible haematuria with clots (urological malignancy until excluded)
  • Haematuria with weight loss, flank mass or bone pain
  • Red cell casts/dysmorphic cells with rising creatinine (glomerulonephritis)
  • Haematuria with fever and loin pain (infected obstruction)
  • New proteinuria with haematuria

Assessment

Differential diagnosis

  • Urological malignancy (bladder, renal, prostate)
  • Urinary tract infection
  • Nephrolithiasis
  • Glomerular disease (IgA nephropathy, thin GBM, Alport)
  • BPH / urethral/prostatic bleeding
  • Exercise-induced or menstrual contamination

Investigations

  • Urinalysis and microscopy (dysmorphic RBCs, red cell casts, proteinuria)
  • Urine culture (exclude infection) and repeat dipstick after treating UTI
  • Urine ACR/PCR and renal function
  • Blood pressure
  • Renal tract imaging (ultrasound or CT urogram) per risk
  • Flexible cystoscopy for visible haematuria or high-risk non-visible haematuria

Management

  • Confirm true haematuria (positive dipstick with red cells on microscopy; exclude myoglobin/haemoglobin and contamination)
  • Treat and recheck if urinary tract infection is present
  • Classify as visible or non-visible (symptomatic vs asymptomatic) haematuria
  • Look for glomerular clues: dysmorphic red cells, red cell casts, proteinuria, hypertension, impaired function
  • Refer all visible haematuria (without clear infective cause) and high-risk non-visible haematuria for urological assessment including cystoscopy and upper-tract imaging
  • Refer patients with glomerular features (proteinuria, casts, raised creatinine) to nephrology
  • Use CT urogram for upper-tract imaging where malignancy risk is higher (age, smoking)
  • Investigate and manage identified stones, tumours or infection appropriately
  • For isolated non-visible haematuria without glomerular or urological cause, monitor BP, eGFR and ACR periodically
  • Address cardiovascular and renal risk in persistent glomerular haematuria
  • Reassess if proteinuria or function changes over time
  • Document a clear surveillance or discharge plan

Drugs & doses

Culture-directed antibiotics for confirmed UTI (e.g. nitrofurantoin 100 mg MR PO twice daily for 3-7 days)
ACE inhibitor/ARB if glomerular haematuria with proteinuria/hypertension (e.g. ramipril 2.5-10 mg PO daily)

Disposition

Urology referral for visible/high-risk haematuria (two-week-wait pathways where cancer suspected); nephrology for glomerular patterns. Monitor isolated benign non-visible haematuria in primary care.

Complications & pitfalls

  • Missed urological malignancy
  • Progressive glomerular disease if nephrological cause overlooked
  • Anaemia from significant bleeding/clot retention
  • Obstruction from clots
  • Delayed diagnosis from attributing to anticoagulation alone

Exam pearls

  • Dysmorphic red cells and red cell casts point to a glomerular (nephrology) cause
  • Visible haematuria needs urological work-up even if the patient is anticoagulated — do not just blame the warfarin
  • Always exclude and re-test after UTI before extensive work-up
  • Proteinuria alongside haematuria raises the chance of significant glomerular disease
  • Smoking and age raise urothelial cancer risk — lower the threshold for cystoscopy/CT urogram

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.